(Q38455433)

English

Evaluation of HER-2/NEU protein expression in breast cancer by immunohistochemistry: an interlaboratory study assessing the reproducibility of HER-2/NEU testing

scientific article published on July 2002

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Evaluation of HER-2/NEU protein expression in breast cancer by immunohistochemistry: an interlaboratory study assessing the reproducibility of HER-2/NEU testing (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

immunohistochemistry

1 reference

based on heuristic

inferred from title

reproducibility

1 reference

based on heuristic

inferred from title

Fátima Cardoso

5

object named as

Fatima Cardoso

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

author name string

David Gancberg

1

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Tero Järvinen

2

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Angelo di Leo

3

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Ghizlane Rouas

4

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Marianne Paesmans

6

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Alain Verhest

7

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Martine J Piccart

8

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Jorma Isola

9

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Denis Larsimont

10

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

language of work or name

0 references

publication date

1 July 2002

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Breast Cancer Research and Treatment

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

74

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

113-120

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

describes a project that uses

immunohistochemistry

1 reference

based on heuristic

inferred from title

https://scigraph.springernature.com/pub.10.1023/a:1016146130767

0 references

Molecular mechanisms underlying ErbB2/HER2 action in breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016146130767

21 January 2018

Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016146130767

21 January 2018

Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016146130767

21 January 2018

Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016146130767

21 January 2018

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016146130767

7 January 2021

based on heuristic

inferred from DOI database lookup

Overexpression of ErbB2 in cancer and ErbB2-targeting strategies

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016146130767

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016146130767

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016146130767

7 January 2021

based on heuristic

inferred from DOI database lookup

Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016146130767

7 January 2021

based on heuristic

inferred from DOI database lookup

c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016146130767

7 January 2021

based on heuristic

inferred from DOI database lookup

erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016146130767

7 January 2021

based on heuristic

inferred from DOI database lookup

erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016146130767

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of HER-2/neu on chemosensitivity of tumor cells

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016146130767

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016146130767

7 January 2021

based on heuristic

inferred from DOI database lookup

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016146130767

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016146130767

7 January 2021

based on heuristic

inferred from DOI database lookup

Assessment of HER2 status in breast cancer: why, when and how?

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016146130767

7 January 2021

based on heuristic

inferred from DOI database lookup

ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016146130767

7 January 2021

based on heuristic

inferred from DOI database lookup

HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016146130767

7 January 2021

based on heuristic

inferred from DOI database lookup

Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016146130767

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016146130767

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative methodological analysis of erbB-2/HER-2 gene dosage, chromosomal copy number and protein overexpression in breast carcinoma tissues for diagnostic use

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016146130767

7 January 2021

based on heuristic

inferred from DOI database lookup

HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016146130767

7 January 2021

based on heuristic

inferred from DOI database lookup

HER-2/neu protein expression in breast cancer evaluated by immunohistochemistry. A study of interlaboratory agreement

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016146130767

7 January 2021

based on heuristic

inferred from DOI database lookup

Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016146130767

7 January 2021

based on heuristic

inferred from DOI database lookup

Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016146130767

7 January 2021

based on heuristic

inferred from DOI database lookup

Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016146130767

7 January 2021

based on heuristic

inferred from DOI database lookup

Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016146130767

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunohistochemical determination of HER-2/neu expression in invasive breast carcinoma.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016146130767

7 January 2021

based on heuristic

inferred from DOI database lookup

C-erbB-2 immunostaining: problems with interpretation

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016146130767

7 January 2021

based on heuristic

inferred from DOI database lookup

Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas. Correlation with oncogene amplification in 160 cases

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016146130767

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased HER2 with U.S. Food and Drug Administration-approved antibody

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016146130767

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of antigen retrieval by microwave heating in formalin-fixed tissue sections on a broad panel of antibodies

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016146130767

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1023/A:1016146130767

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38455433&oldid=1878982209"